New data reveals optimal timing for percutaneous coronary intervention in TAVR patients

FHS
May 4, 2024
3:40 am

New data reveals that percutaneous coronary intervention (PCI) can be safely performed before, during, or after transcatheter aortic valve replacement (TAVR) for patients with stable coronary artery disease (CAD).

Pot smell and safety concerns ignite disputes over public smoking – The Cannabist

Related Articles By Kevin Hardy, Stateline.org Carl Sack is no fan of marijuana. He tried smoking once in high school and hasn’t touched it since.

August 22, 2023

How one scientist’s determination made Novo Nordisk an obesity-drug powerhouse

Lotte Bjerre Knudsen was still getting used to all the empty benches in her lab when she ran into a tall man with black wide-framed

October 17, 2023

AstraZeneca concludes equity investment in Cellectis

AstraZeneca maintains an option for a global exclusive licence for the candidate products developed through the deal. Credit: Robert Way / Shutterstock.com. AstraZeneca has concluded

May 7, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.